Drug repurposing for new treatments of rare diseases: the academic, biotech, and investor perspective

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
The repurposing of existing drugs is an established approach to develop new treatment options for rare diseases. The path towards market authorization is potentially shortened (and less expensive) when molecules shelved for non-safety reasons come with previously collected experimental data (e.g. tox studies, IND). The other side of the coin is that the lifetime of the patent is often limited or has run out, which demands creative business models to provide a return on investments.

In this session, success stories and current challenges will be shared from the academic, governmental, biotech, and venture capital perspective. Presentations by the speakers will be followed by a panel discussion, while also giving the audience the chance to ask the panel questions.
Moderator
photo
Business Development Manager
EATRIS
Speakers
photo
Director, Division of Preclinical Innovation, Therapeutic Development Branch, National Center for Advancing Translational Sciences
National Institutes of Health
photo
Founder & President, R&D
Cydan
photo
President & CEO
Laurent Pharmaceuticals
photo
Business Development Manager
EATRIS